Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults

Pfizer (PFE) announced positive top-line data from substudy B of the ongoing pivotal late-stage MONeT study. The study is evaluating two doses of its RSV vaccine Abrysvo in immunocompromised adults who are at risk of developing severe RSV-associated lower respiratory tract disease (LRTD).While this substudy evaluated two 120 µg doses of Abrysvo, management reported that a single dose of the vaccine generated strong neutralizing responses against both RSV subtypes (RSV-A and RSV-B) across all cohorts and age ...